Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Oncology | Pharmacy | Institutional

Back to Journal Articles

Cometriq Approved for Medullary Thyroid Cancer

Last Updated: November 30, 2012.

 

Cometriq (cabozantinib) is kinase inhibitor approved for metastatic medullary thyroid cancer

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 

FRIDAY, Nov. 30 (HealthDay News) -- Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat metastatic medullary thyroid cancer, the agency said Thursday.

The medullary form accounts for about 4 percent of the more than 56,000 cases of thyroid cancer diagnosed annually in the United States, the FDA said in a news release.

Cometriq is a kinase inhibitor that's designed to block the effects of proteins involved in cancer cell development and growth. People should not eat at least two hours before, and one hour after, taking the drug, the agency said.

Cometriq's safety and effectiveness was evaluated in clinical studies involving 330 people with medullary thyroid cancer. Those given Cometriq lived an average of 11.2 months without tumor growth, compared with an average of four months of progression-free survival among people who took a placebo. The drug "did not extend patients' lives," the FDA said.

The product's label has a boxed warning of the potential for severe and fatal bleeding of the colon, the FDA added.

More common and less serious side effects may include diarrhea, mouth sores, redness and swelling of the fingers or toes, weight loss, appetite suppression, and nausea.

Cometriq is marketed by Exelixis, based in San Francisco.

More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Materialism, Impulsiveness Impact Technology Addictions Next: Urban HIV Infection Mainly Due to Male-Male Sexual Contact

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.